- Home
- VOXR vs CERS Comparison
VOXR vs CERS Comparison
Compare VOXR & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOXR
- CERS
- Stock Information
- Founded
- VOXR 2014
- CERS 1991
- Country
- VOXR United States
- CERS United States
- Employees
- VOXR N/A
- CERS N/A
- Industry
- VOXR Precious Metals
- CERS EDP Services
- Sector
- VOXR Basic Materials
- CERS Technology
- Exchange
- VOXR Nasdaq
- CERS Nasdaq
- Market Cap
- VOXR 293.7M
- CERS 276.0M
- IPO Year
- VOXR N/A
- CERS 1997
- Fundamental
- Price
- VOXR $3.90
- CERS $1.41
- Analyst Decision
- VOXR
- CERS Buy
- Analyst Count
- VOXR 0
- CERS 1
- Target Price
- VOXR N/A
- CERS $4.00
- AVG Volume (30 Days)
- VOXR 584.2K
- CERS 1.1M
- Earning Date
- VOXR 11-06-2025
- CERS 11-06-2025
- Dividend Yield
- VOXR 1.27%
- CERS N/A
- EPS Growth
- VOXR N/A
- CERS N/A
- EPS
- VOXR N/A
- CERS N/A
- Revenue
- VOXR $10,771,473.00
- CERS $192,510,000.00
- Revenue This Year
- VOXR $46.18
- CERS $19.07
- Revenue Next Year
- VOXR $86.32
- CERS $12.03
- P/E Ratio
- VOXR N/A
- CERS N/A
- Revenue Growth
- VOXR N/A
- CERS 13.25
- 52 Week Low
- VOXR $2.21
- CERS $1.12
- 52 Week High
- VOXR $4.76
- CERS $2.24
- Technical
- Relative Strength Index (RSI)
- VOXR 42.72
- CERS 43.55
- Support Level
- VOXR $3.88
- CERS $1.48
- Resistance Level
- VOXR $4.36
- CERS $1.54
- Average True Range (ATR)
- VOXR 0.17
- CERS 0.07
- MACD
- VOXR -0.06
- CERS -0.02
- Stochastic Oscillator
- VOXR 5.63
- CERS 12.50
About VOXR Vox Royalty Corp.
Vox Royalty Corp is a returns-focused mining royalty company with a portfolio of royalties and streams spanning eight jurisdictions. It has built intellectual property, a technically focused transactional team, and a sourcing network which has allowed Vox to target the highest returns on royalty acquisitions in the mining royalty sector. The company geographically operates Australia, Nigeria, USA, and Brazil.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.